Yuhan Corporation announced on October 20 that it has published a comprehensive history titled 'Yuhan 100-Year History' to commemorate its centennial anniversary.
The book chronicles the growth, research and development achievements, and social contributions of Yuhan Corporation since its founding by the late Dr. Il-han Yoo in 1926. It consists of three volumes: a general history, a history of research and development, and a commemorative photo book.
The general history covers key events in the company's journey from 'the birth of a national enterprise, Yuhan Corporation' to 'becoming a global pharmaceutical company centered on R&D,' detailing 100 stories across ten chapters. It addresses significant changes, including the company's early efforts to distribute essential medicines, its initial public offering (IPO) as the first in the pharmaceutical industry, the establishment of a professional management system, and its commitment to social responsibility.
The research and development volume summarizes the product development process and R&D achievements in three chapters. It particularly highlights the lung cancer treatment drug 'Lazartin' (ingredient name: Lazertinib), developed through collaboration with external biotech firms in an open innovation model. Lazartin became the first domestically developed anticancer drug to receive approval from the U.S. Food and Drug Administration (FDA) and is marketed in the U.S. under the name 'Razcluiz.' The drug has also entered overseas markets, and the volume discusses future growth projects, including next-generation immuno-oncology drugs, candidates for metabolic disease treatments, and the expansion of contract development and manufacturing organization (CDMO) services for active pharmaceutical ingredients.
The commemorative photo book includes records of a campaign to collect historical materials, commemorative events, the production of webtoons and documentaries, the launch of commemorative products, and various competitions, along with photographs documenting these activities.
According to the consensus from FnGuide, Yuhan Corporation's consolidated revenue for the third quarter of this year is projected to be 608.5 billion won, with an operating profit of 32.6 billion won, reflecting increases of 6.76% and 47.99%, respectively, compared to the same period last year.
Yuhan Corporation plans to distribute the 100-year history to major national and public libraries and university libraries across the country.
A Yuhan Corporation representative stated, "The Yuhan 100-Year History is a record that goes beyond the history of a single company, encapsulating the development of the Korean pharmaceutical and bio industry and the values of sharing and integrity championed by Dr. Il-han Yoo. We aim to contribute to human health based on the trust we have built over the past century."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.